Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of obinutuzumab in systemic lupus erythematosus
2020-005760-57Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Obinutuzumab with Placebo (2 arms). Primary endpoint: Percentage of participants who achieve SRI (4) at Week 52. Started Jun 2021; status: active.
02
Drugs
obinutuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2020-005760-57.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005760-57.